Andrx' Concerta Generic Likely Blocked By Another ANDA Filer's Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J recently listed a new patent for Concerta, and another generic company appears to hold 180-day exclusivity based on that patent, Andrx says.
You may also be interested in...
J&J Dismisses Concerta Patent Suit Against Impax
"Odd" case against the first-filer ends, but litigation with Andrx continues.
J&J Dismisses Concerta Patent Suit Against Impax
"Odd" case against the first-filer ends, but litigation with Andrx continues.
J&J Plans Dapoxetine Meeting With FDA, Awaits Agency Actions
Firm’s pharma sales stall as it awaits FDA action on pending NDAs and Concerta citizen petition.